A long-term follow-up of evolocumab in patients with familial hypercholesterolemia (FH) has found the PCSK9 inhibitor is well tolerated and effective in reducing LDL-C levels. The open-label single-arm study comprised 300 patients as young as 12 years with either homozygous or severe heterozygous FH and receiving stable lipid lowering therapy including statins and ezetimibe in ...
What the long term data tells us about evolocumab in FH
By Mardi Chapman
27 Feb 2020